Status:
COMPLETED
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
Lead Sponsor:
Allergan
Conditions:
Atopic Conjunctivitis
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye). The study consists of a doub...
Eligibility Criteria
Inclusion
- Have a clinical diagnosis of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye)
- Be on stable doses of your current AKC medications for at least 2 weeks
Exclusion
- You have used contact lenses within 48 hours of Day 1 or think you may have to wear contact lenses during the study
- You are pregnant, breastfeeding, or planning to become pregnant during the study
- You have used a calcineurin inhibitors (e.g. topical tacrolimus or topical pimecrolimus) on or around your eyes including eyelids within 4 weeks
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT00884585
Start Date
May 1 2009
End Date
July 1 2011
Last Update
November 5 2012
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Bakersfield, California, United States
2
Randwick, New South Wales, Australia
3
Ottawa, Ontario, Canada
4
Prague, Czechia